Condition category
Urological and Genital Diseases
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Plain English Summary

Background and study aims
In Northern Ireland the rising number of patients with both chronic kidney disease (CKD) and heart disease is explained by many risk factors. These include age, high blood pressure, diabetes and obesity. Around 6000 coronary dye tests are performed each year in Northern Ireland. 20% of patients tested will have CKD and are at high risk of kidney damage due to the harmful dye used (contrast-induced nephropathy - CIN). Contrast dye is toxic to the kidney. Unfortunately there is no alternative to it and the number of patients who develop this complication is set to rise.

Acute kidney injury (AKI) is best avoided; once developed it dramatically increases risk of death, length of hospital stay and healthcare costs. Current tests fail to detect early AKI and there is a need for new markers of kidney damage. Neutrophil gelatinase associated lipocalin (NGAL) has the potential to detect AKI within a few hours of onset; we aim to study it in a high-risk CKD population.

This study aims to find out whether NGAL could be a useful marker of early CIN and see if it can predict severity of CIN, and to see if NGAL could be used to identify those at high risk of CIN.

Who can participate?
Patients at high risk of CIN will be identified prior to cardiac catheterisation at Craigavon Area Hospital between October 2011 and August 2013. All patients over the age of 18 with existing chronic renal failure, as shown by abnormal blood tests before the dye test, will be invited to take part. Men and women will both be invited.

What does the study involve?
A fluid drip will be given to help protect kidney function before the dye test. Blood samples will be collected directly before and after the dye test, and at 2, 4, 6, 24 and 48 hour time-points. Additional blood will be stored for possible future testing.

What are the possible benefits and risks of participating?
New markers to detect AKI early would help to treat patients who develop AKI sooner. If realised, this research has the potential to dramatically increase the safety of coronary dye testing and could greatly benefit patients both in Northern Ireland and further afield. The only risk to patients will be that of serial blood sampling, which may cause minor bleeding, pain or bruising. This will be reduced by using the smallest needle possible. All patients will have the same treatment.

Where is the study run from?
Craigavon Area Hospital (UK).

When is the study starting and how long is it expected to run for?
The study will run from October 2011 to August 2013.

Who is funding the study?
RANDOX laboratories.

Who is the main contact?
Dr Michael Connolly
Research Fellow
Cardiac Research
Craigavon Area Hospital

Trial website

Contact information



Primary contact

Dr David Mc Eneaney


Contact details

Cardiology Unit
Craigavon Area Hosptial
68 Lurgan Road
BT63 5QQ
United Kingdom
+44 (0)2838 334 444

Additional identifiers

EudraCT number number

Protocol/serial number

1.1 19/08/2011

Study information

Scientific title

Neutrophil Gelatinase Associated Lipocalin (NGAL) as a predictor of acute kidney injury post coronary angiogram: a cohort observational study


Study hypothesis

Raised levels of NGAL at 4 hours post contrast angiogram will predict acute kidney injury, as evidenced by a rise in creatinine > 25% at 48 hours.

Ethics approval

Not provided at time of registration

Study design

Cohort observational study

Primary study design


Secondary study design

Non randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Chronic Renal Disease


Samples for serum and urine NGAL, serum cystatin C and serum creatinine will be collected directly pre- and post-contrast angiogram, and at 2, 4, 6, 24 and 48 hr time-points to allow time course analysis post catheterisation.

Patients will be followed up at 30 days and 1 year.

Intervention type



Not Applicable

Drug names

Primary outcome measure

Post procedure biomarker elevation diagnostic for acute kidney injury

Secondary outcome measures

Major cardiac adverse events (MACE) at 30 days and one year:
1. Myocardial infarction
2. Stroke
3. Heart failure hospitalisation
4. Death

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Age > 18 years
2. Presenting for angiogram with known chronic kidney disease (CKD) [glomerular filtration rate (GFR) < 60mls/min]

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. Myocardial infarction (MI) or acute coronary syndrome within previous 6 weeks
2. Hospitalisation within previous 6 weeks
3. Decompensated heart failure
4. Inability to give informed consent

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Cardiology Unit
BT63 5QQ
United Kingdom

Sponsor information


Randox Laboratories (UK)

Sponsor details

55 Diamond Road
BT29 4QY
United Kingdom
+44 (0)2894 422 413

Sponsor type




Funder type


Funder name

Randox Laboratories (UK)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

2018 results in: [added 18/01/2019]

Publication citations

Additional files

Editorial Notes

18/01/2019: Publication reference added. 24/08/2016: No publications found, verifying study status with principal investigator